Journals / Türk Kardiyoloji Derneği Arşivi / 2017 / Cilt: 45 - Sayı: Suppl. 5

Polypharmacy and drug interactions in elderly patients

Yaşlı hastalarda polifarmasi ve ilaç etkileşimi

Pages
17–21
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The most important point to prevent polypharmacy is to inform the patient or the patient’s caregiver fully and to target treatment with a minimum number of drugs and doses.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Although the definition of polypharmacy is not yet clear today, it is generally regarded as drug use more than the patient needs.
📊
Key Findings & Data:It is seen in about 40% of people over 75 years of age worldwide, varying between countries of extreme poverty.
💡
Conclusion & Impact:The most important point to prevent polypharmacy is to inform the patient or the patient’s caregiver fully and to target treatment with a minimum number of drugs and doses.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Although the definition of polypharmacy is not yet clear today, it is generally regarded as drug use more than the patient needs. Advanced age is the most important risk factor for polypharmacy. In addition, other risk factors are loss of current cognitive functions, low socioeconomic level and nursing care. It is seen in about 40% of people over 75 years of age worldwide, varying between countries of extreme poverty. Incorrect drug use, drug side effects and drug-drug interaction lead to unwanted hospitalizations. In particular, cardiovascular drugs pose risks in terms of drug side effects in advanced ages. Altering the pharmacokinetics and pharmacodynamics of the drug along with advanced age lead to more frequent side effects or no effect of the drugs. The most important point to prevent polypharmacy is to inform the patient or the patient’s caregiver fully and to target treatment with a minimum number of drugs and doses.

Özet

Polifarmasi tanımlaması günümüzde henüz net bir şekilde yapılamamış olsa da genel olarak hastanın ihtiyacı olduğundan fazla ilaç kullanması olarak kabul edilir. İlerleyen yaş polifarmasi için en önemli risk faktörüdür. Ayrıca hastada mevcut bilişsel fonksiyonların kaybı, düşük sosyoekonomik düzey ve huzurevinde kalma diğer risk faktörleridir. Sıklığı ülkeler arasında değişmekle birlikte dünya genelinde 75 yaş üzeri kişilerde %40 dolaylarında görülmektedir. Yanlış ilaç kullanımı, ilaç yan etkileri ve ilaç-ilaç etkileşimi istenmeyen hastane yatışlarına yol açmaktadır. Özellikle kardiyovasküler ilaçlar ilerleyen yaşlarda ilaç yan etkileri açısından risk oluşturmaktadır. İleri yaş ile birlikte ilacın farmakokinetik ve farmakodinamiğinin değişmesi ilaçların daha sık yan etki göstermesine veya etki göstermemesine yol açmaktadır. Polifarmasiyi önlemek için üzerinde durulması gereken en önemli nokta hasta veya hasta bakıcısının tam olarak bilgilendirilmesi ve minimum sayıda ilaç ve doz ile tedavi hedeflenmesidir.

🔖

Cite This Article

KILINÇ, A. Y., YILDIRIM, A. B. (2022). Polypharmacy and drug interactions in elderly patients. Türk Kardiyoloji Derneği Arşivi, Cilt: 45 - Sayı: Suppl. 5, 17–21. https://ajindex.com/articles/632353

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Friend DG. Polypharmacy; multiple-ingredient and shotgun prescriptions. N Engl J Med 1959;260:1015–18
  2. Veehof L, Stewart R, Haaijer-Ruskamp F, Jong BM. The development of polypharmacy. A longitudinal study. Fam Pract 2000;17:261–7
  3. United Kingdom Department of Health. Medicines and older people: implementing medicines-related aspects of the The National Service of Framework (NSF) for older people. 2001. Available at: http://webarchive.nationalarchives. gov.uk/20130107105354/http:/www.dh.gov.uk/en/Publicationsandstatistics/ Publications/PublicationsPolicyAndGuidance/DH_4008020
  4. Fillit HM, Futterman R, Orland BI, Chim T, Susnow L, Picariello GP, et al. Polypharmacy management in Medicare managed care: changes in prescribing by primary care physicians resulting from a program promoting medication reviews. Am J Manag Care 1999;5:587–94
  5. Viktil KK, Blix HS, Moger TA, Reikvam A. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol 2007;63:187–95
  6. Tjia J, Velten SJ, Parsons C, Valluri S, Briesacher BA. Studies to reduce unnecessary medication use in frail older adults: a systematic review. Drugs Aging 2013;30:285–307
  7. Rochon PA, Schmader KE, Sokol HN. Drug prescribing for older adults (2012). Available at: https://www.uptodate.com/contents/drug-prescribing-for-olderadults. Accessed July 20, 2017
  8. Lindley CM, Tully MP, Paramsothy V, Tallis RC. Inappropriate medication is a major cause of adverse drug reactions in elderly patients. Age Ageing 1992;21:294–300
  9. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 2008;300:2867–78
  10. Ramage-Morin PL. Medication use among senior Canadians. Health Rep 2009;20:37–44
  11. Morin L, Vetrano DL, Rizzuto D, Calderón-Larrañaga A, Fastbom J, Johnell K. Choosing Wisely? Measuring the Burden of Medications in Older Adults near the End of Life: Nationwide, Longitudinal Cohort Study. Am J Med 2017;130:927–36.e9
  12. Nobili A, Licata G, Salerno F, Pasina L, Tettamanti M, Franchi C, et al; SIMI Investigators. Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. Eur J Clin Pharmacol 2011;67:507–19
  13. Shah BM, Hajjar ER. Polypharmacy, adverse drug reactions, and geriatric syndromes. Clin Geriatr Med 2012;28:173–86. 1